



Markus Joerger

Contact

Markus Joerger

Publications (6)

Addeo A, Rothschild S, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann P, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh M. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. *Lung Cancer* 2022; 172:154-159.

Jacobs B, Deenen M, Joerger M, Rosing H, de Vries N, Meulendijks D, Cats A, Beijnen J, Schellens J, Huitema A. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis. *CPT Pharmacometrics Syst Pharmacol* 2019; 8:940-950.

Kraff S, Lindauer A, Joerger M, Salamone S, Jaehde U. Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. *Ther Drug Monit* 2015; 37:725-32.

Joerger M. Treatment regimens of classical and newer taxanes. *Cancer Chemother Pharmacol* 2015; 77:221-33.

Kummer D, Froehlich T, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr C. Dihydropyrimidinase and β -ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. *Pharmacogenomics* 2015; 16:1367-77.

Amstutz U, Offer S, Sistonen J, Joerger M, Diasio R, Largiadèr C. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. *Clin Cancer Res* 2015; 21:2038-44.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch